mefloquine

GPTKB entity

Statements (54)
Predicate Object
gptkbp:instance_of gptkb:immunotherapy
gptkbp:approves gptkb:1989
gptkb:FDA
gptkbp:atccode P01 BC03
gptkbp:availability prescription only
gptkbp:brand gptkb:Lariam
gptkbp:category gptkb:C
gptkbp:chemical_formula C17 H16 Cl2 FN3 O
gptkbp:class quinoline
gptkbp:clinical_trial Phase IV
Phase III
gptkbp:composed_by synthetic compound
gptkbp:contraindication history of psychiatric disorders
history of seizures
gptkbp:developed_by gptkb:Walter_Reed_Army_Institute_of_Research
gptkbp:discovery_year 1970s
gptkbp:dosage_form 15 mg/kg for treatment
250 mg once a week
gptkbp:duration 3 days for acute malaria
4 weeks for prophylaxis
gptkbp:excretion urine
https://www.w3.org/2000/01/rdf-schema#label mefloquine
gptkbp:interacts_with antidepressants
beta-blockers
anticonvulsants
gptkbp:lifespan approximately 20 days
gptkbp:marketed_as gptkb:Lariam
gptkbp:mechanism_of_action inhibits heme polymerization
gptkbp:metabolism liver
gptkbp:name essential medicines
gptkbp:research_areas malaria prevention
treatment of drug-resistant malaria
gptkbp:route_of_administration oral
gptkbp:safety_measures post-marketing surveillance
gptkbp:side_effect gptkb:depression
anxiety
dizziness
fatigue
headache
nausea
abdominal pain
fever
vomiting
gastrointestinal disturbances
rash
insomnia
cardiac arrhythmias
hepatotoxicity
visual disturbances
gptkbp:used_for treatment of malaria
prevention of malaria
gptkbp:water_resistance possible with prolonged use
gptkbp:bfsParent gptkb:artemisinin-based_therapies
gptkbp:bfsLayer 7